1TB.F 164.5 (-0.6%)

Orphazyme (1TB.F) Stock Highlights

164.5 | -0.6%
2024-01-11 03:28:40
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The companys lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).


Range Today
164.5 164.5
Volume Today 0
Range 1 Year
84.8 457.5
Volume 1 Year 40
Range 3 Year
84.8 16500
Volume 3 Year 368
Range 10 Year
84.8 91900
Volume 10 Year 378


Market Capitalization 37.27M (micro)
Floating Shares 25.8K
Current Price 164.5
Price To Earnings 0
Price To Book 0
Earnings Per Share -2.29K
Payout Ratio 0%


Latest -0.6%
1 Month +83.8%
3 Months +40.12%
6 Months -21.48%
1 Year +47.4%
3 Years -98.11%
5 Years -97.32%
10 Years -97.32%


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.